Ascendis Pharma A/S (NASDAQ:ASND) Price Target Increased to $160.00 by Analysts at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price target upped by TD Cowen from $157.00 to $160.00 in a research report released on Monday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

ASND has been the subject of a number of other reports. Citigroup raised their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Jefferies Financial Group lifted their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research report on Tuesday, August 13th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Oppenheimer reissued an “outperform” rating and issued a $190.00 price objective (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $195.23.

Ascendis Pharma A/S Trading Down 1.0 %

Ascendis Pharma A/S stock opened at $128.66 on Monday. Ascendis Pharma A/S has a 12-month low of $85.29 and a 12-month high of $161.00. The firm has a 50-day moving average price of $135.54 and a 200-day moving average price of $135.01. The firm has a market capitalization of $7.49 billion, a PE ratio of -13.32 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. As a group, sell-side analysts predict that Ascendis Pharma A/S will post -7.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in the company. Private Ocean LLC purchased a new position in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $36,000. GAMMA Investing LLC grew its holdings in Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 102 shares during the last quarter. Signaturefd LLC increased its position in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Finally, Searle & CO. purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter valued at $205,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.